🔊CEOInterviews

Jean-jacques Bienaimé on diversity, equity & inclusion

From Lead From the Heart – Jean Jacques Bienaime · · SpreadLoveio

“We are going to have a DEI initiative because it's fundamental to the success of the business and the right thing to do — but we want to make sure we take the politics out of it.”

Jean-jacques Bienaimé
Former CEO, BioMarin
Controversial Policy Impact diversity, equity & inclusioncorporate governancepolitics

On , Jean-jacques Bienaimé, Former CEO at BioMarin, spoke about diversity, equity & inclusion during Lead From the Heart – Jean Jacques Bienaime on SpreadLoveio.

Lead From the Heart – Jean Jacques Bienaime
Watch on YouTube at 39:38
Lead From the Heart – Jean Jacques Bienaime
SpreadLoveio
Watch on YouTube at 39:38
This episode is special and the first in a series of three. In partnership with ESCP Business School, I'll be giving the mic to ...
Jean-jacques Bienaimé

About Jean-jacques Bienaimé

Former CEO · BioMarin

Jean-Jacques Bienaimé, former CEO and chairman of BioMarin Pharmaceutical, has discussed the company's development of gene therapies and its approach to drug pricing. In 2023, he stated that the company's gene therapy for hemophilia A showed positive trial results, with patients experiencing a 98% reduction in factor infusions and a decrease in bleeding episodes from 4.6 per year to less than one. He described the results as "as good as we could hope" and said the therapy would be a "transformational treatment" for patients. Bienaimé also commented on the broader biotech industry, saying that some venture-capital-funded biotech companies "probably should not be on the market today" and predicted a consolidation. Bienaimé has addressed the company's pricing strategy for its therapies, stating that the goal is to recoup investment while ensuring the healthcare system and patients save money compared to existing treatments. He noted that existing therapies for hemophilia cost around $500,000 per year in the U.S. and said BioMarin planned to use outcomes-based agreements to guarantee success. Reflecting on his tenure, Bienaimé acknowledged that the company became "overconfident" in its ability to get products approved after a history of success, which he described as a "mistake but a learning experience." He has also emphasized the importance of employees, patients, and investors, stating that "employees are the oxygen of any company."

Profile compiled from Jean-jacques Bienaimé's verified public interviews and appearances. See all quotes & transcripts →

This quote was transcribed and extracted with AI assistance from a verified, first-person interview, then reviewed by our team to confirm the speaker and the exact wording. See how we verify →

More from Jean-jacques Bienaimé Full Transcript Explore All Executives